The microarray technology segment will witness substantial growth due to associated
advantages offered such as, comparison of thousands of genes at once, powerful
technology for sequenced genome, and gene expression studies. Additionally, there is
no requirement of expensive and tedious process of positioning thus large batches
production is possible.
Browse key industry insights from the report “Biochips Market Size, Industry
Analysis Report, Regional Outlook (U.S., Canada, Germany, France, Italy, UK,
Spain, Russia, China, India, Japan, South Korea, Australia, New Zealand, Singapore,
Argentina, Brazil, Mexico, South Africa, U.A.E, Saudi Arabia), Application
Development Potential, Price Trends, Competitive Market Share & Forecast, 2017
– 2024” in detail along with the table of contents:
https://www.gminsights.com/industry-analysis/biochips-market
Diagnostic centers and hospitals segment is growing efficiently with increasing demand
in genomic testing and gene expression for detection of genetic disorders. In addition,
the adoption by other fields for application in environmental contamination, biodefense,
and identification of food pathogen upsurge biochips market growth.
U.S. held largest revenue share in 2016, owing to high adoption rate of the advanced
technology in the fields of proteomics and genomics. Moreover, rising R&D activities
along with supporting funds provided for research are the factors propelling business
growth. For instance, at the Argonne National Laboratory, U.S. Department of Energy,
researchers succeeded in progress of biochip to diagnose modifications of cancer before
patient show any similar symptoms of cancer.
Germany will witness lucrative growth due to rising demand for advanced diagnosis,
ongoing R&D, and technological advancement. For instance, at Heinz Nixdorf Chair, in
Germany, work on controlling tumor growth by using biochip technology is done. This
can be implanted near tumor for release of drugs when the tumor grows and it will be
controlled by electrical impulses, thereby, treating patients that cannot be operated for
pancreatic cancerous tumors.
Some of the industry players are PerkinElmer, Illumina, Bio-Rad Laboratories, Agilent
Technologies, Thermo Fisher Scientific, Abbott Laboratories, F. Hoffmann-La Roche,
Becton Dickinson and Company, Origene Technologies, and Novus Biologicals. The
company players concentrate on strategic partnership, and acquisitions for their
development. For instance, in August 2015, Becton Dickinson acquired Cellular
Research that is a startup and it develops tools for single cell genetic analysis created on
technology of molecular indexing.
2 | Page